HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnabei, V. M. Search for Related Content PubMed PubMed Citation Articles by Barnabei, V. M. Related Collections Menopause and HRT

Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative

OBJECTIVE: To estimate the effects of estrogen plus progestin (E+P) therapy on menopausal symptoms, vaginal bleeding, gynecologic surgery rates, and treatment-related adverse effects in postmenopausal women.

METHODS: Randomized, double-blind, placebo-controlled trial of 16,608 postmenopausal women, ages 50–79 (mean ± standard deviation 63.3 ± 7.1) years, with intact uterus, randomized to one tablet per day containing 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate (n = 8,506) or placebo (n = 8,102), and followed for a mean of 5.6 years. Change in symptoms and treatment-related effects were analyzed at year 1 in all participants. Bleeding and gynecologic surgery rates were analyzed through study close-out.

RESULTS: Baseline symptoms did not differ between the treatment groups. More women assigned to E+P than placebo reported relief of hot flushes (85.7% versus 57.7%, respectively; odds ratio 4.40; 95% confidence interval 3.40–5.71), night sweats (77.6% versus 57.4%; 2.58; 2.04–3.26), vaginal or genital dryness (74.1% versus 54.6%; 2.40; 1.90–3.02), joint pain or stiffness (47.1% versus 38.4%; 1.43; 1.24–1.64), and general aches or pains (49.3% versus 43.7%; 1.25; 1.08–1.44). Women asymptomatic at baseline who were assigned to E+P more often developed breast tenderness (9.3% versus 2.4%, respectively; 4.26; 3.59–5.04), vaginal or genital discharge (4.1% versus 1.0%; 4.47; 3.44–5.81), vaginal or genital irritation (4.2% versus 2.8%; 1.52; 1.27–1.81), and headaches (5.8% versus 4.7%; 1.26; 1.08–1.46) than women on placebo. Estrogen plus progestin treatment prevented the onset of new musculoskeletal symptoms. Vaginal bleeding was reported by 51% of women on E+P and 5% of women on placebo at 6 months; most bleeding was reported as spotting. Gynecologic surgeries (hysterectomy and dilation and curettage) were performed more frequently in women assigned to E+P (3.1% versus 2.5% for hysterectomy, hazard ratio = 1.23, P = .026; 5.4% versus 2.4% for dilation and curettage, hazard ratio = 2.23, P < .001).

CONCLUSION: Estrogen plus progestin relieved some menopausal symptoms, such as vasomotor symptoms and vaginal or genital dryness, but contributed to treatment-related effects, such as bleeding, breast tenderness, and an increased likelihood of gynecologic surgery.

LEVEL OF EVIDENCE: I

This article has been cited by other articles:

				R. C. Thurston, M. R. Sowers, Y. Chang, B. Sternfeld, E. B. Gold, J. M. Johnston, and K. A. Matthews Adiposity and Reporting of Vasomotor Symptoms among Midlife Women: The Study of Women's Health Across the Nation Am. J. Epidemiol., January 1, 2008; 167(1): 78 - 85. [Abstract] [Full Text] [PDF]

				The ESHRE Capri Workshop Group Endometrial bleeding Hum. Reprod. Update, September 1, 2007; 13(5): 421 - 431. [Abstract] [Full Text] [PDF]

				A. Huang, D. Grady, T. Blackwell, and D. Bauer Hot Flushes, Bone Mineral Density, and Fractures in Older Postmenopausal Women Obstet. Gynecol., April 1, 2007; 109(4): 841 - 847. [Abstract] [Full Text] [PDF]

				C. J. Crandall, A. Karlamangla, M.-H. Huang, G. Ursin, M. Guan, and G. A. Greendale Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy Arch Intern Med, August 14, 2006; 166(15): 1578 - 1584. [Abstract] [Full Text] [PDF]

				R. L. Brunner, M. Gass, A. Aragaki, J. Hays, I. Granek, N. Woods, E. Mason, R. Brzyski, J. Ockene, A. Assaf, et al. Effects of Conjugated Equine Estrogen on Health-Related Quality of Life in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Clinical Trial Arch Intern Med, September 26, 2005; 165(17): 1976 - 1986. [Abstract] [Full Text] [PDF]

				J. K. Ockene, D. H. Barad, B. B. Cochrane, J. C. Larson, M. Gass, S. Wassertheil-Smoller, J. E. Manson, V. M. Barnabei, D. S. Lane, R. G. Brzyski, et al. Symptom Experience After Discontinuing Use of Estrogen Plus Progestin JAMA, July 13, 2005; 294(2): 183 - 193. [Abstract] [Full Text] [PDF]